Metabolism

GLP-1 Drugs Linked to Lower Cancer Risk than Insulin

A study of 359,595 adults found lower rates of obesity-related cancers over three years compared to insulin and sulfonylureas.

Published November 10, 2026 Read 2 min 363 words Topic Metabolism
Reviewed by: Dr. Michael Teplitsky, MD · November 2026

Lower Three-Year Cancer Risk Compared to Insulin

Adults starting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) had a lower risk of developing obesity-related cancers over three years than those who started insulin or sulfonylureas. The study, published in JAMA Network Open, evaluated electronic health records from patients with type 2 diabetes.

The difference in estimated cancer risk was 1.25 percentage points compared with insulin. The difference was 1.14 percentage points compared with sulfonylureas over the three-year tracking window.

How Researchers Structured the Health Record Analysis

Researchers analyzed records from 359,595 adults treated at University of Texas Southwestern Medical Center (UT Southwestern Medical Center) between January 1, 2010, and July 31, 2025. The study used a framework called target trial emulation to replicate the design features of a clinical trial using real-world medical data.

Eligible participants had type 2 diabetes with no prior history of obesity-related cancer. The protocol required a washout period of at least 365 days without the evaluated medication before treatment start, ensuring the data reflected new drug initiations rather than ongoing therapy.

  • Metformin
  • Insulin
  • Sulfonylureas
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors

Accounting for Diabetes Severity and Complications

Prescribing decisions often align with how long a person has had diabetes and whether organ damage exists. Patients with advanced kidney or blood vessel disease frequently receive insulin later in their disease progression, which can alter baseline cancer risk.

To address this confounding factor, the team split participants into three tiers based on diabetes severity from low to high. Patients were followed until their first obesity-related cancer diagnosis, death, final clinic visit, or completion of three to five years of follow-up.

Limitations and Comparison with Other Diabetes Drugs

The lower risk estimate appeared specifically against insulin and sulfonylureas, not across every alternative medication. The study did not find this same risk difference when comparing GLP-1 RAs to metformin, SGLT2 inhibitors, or DPP-4 inhibitors.

This research was an observational analysis based on records from a single academic medical center. While the target trial design controlled for recorded severity, observational data cannot establish direct cause and effect. Patients evaluating diabetes medications should review their specific risk factors with their healthcare provider.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
Primary source: View original source — referenced for fact-checking; this analysis is independent editorial content.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black
GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black
GE
View on Amazon →
Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass
Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass
Etekcity
View on Amazon →
Found this useful?

Related Articles

Want medical weight loss instead of another diet?

Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.

See Opt Health's weight-loss program →

Topic updates

Get the weekly metabolic health roundup

Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.

No spam. Unsubscribe anytime.

Understand Your Health Better

Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results

Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.